Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal

A method for ameliorating neurogenic inflammatory pain comprising:

• administering a compound capable of specifically inhibiting αCGRP activity to an animal having neurogenic inflammatory pain symptoms in an amount sufficient to inhibit the αCGRP activity in the animal so that symptoms of neurogenic inflammatory pain are ameliorated.

A method for ameliorating physical opiate withdrawal comprising:

• administering a compound capable of specifically inhibiting αCGRP activity to an animal having physical opiate withdrawal symptoms in an amount and for a time sufficient to inhibit the αCGRP activity in the animal so that symptoms of physical opiate withdrawal are ameliorated.

A method for ameliorating neurogenic inflammatory pain comprising:

• administering a compound capable of specifically inhibiting expression of αCGRP to an animal having neurogenic inflammatory pain symptoms in an amount and for a time sufficient to inhibit the expression of αCGRP in the animal so that symptoms of neurogenic inflammatory pain are ameliorated.

A method for ameliorating physical opiate withdrawal comprising:

• administering a compound capable of specifically inhibiting expression of αCGRP to an animal having physical opiate withdrawal symptoms in an amount and for a time sufficient to inhibit the expression of αCGRP in the animal so that symptoms of physical opiate withdrawal are ameliorated.

A compound for ameliorating neurogenic inflammatory pain an/or physical opiate withdrawal, wherein said compound is an antagonist of calcitonin gene related peptide αCGRP.